(Q28142100)

English

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

scientific article (publication date: October 2000)

In more languages

edit

Statements

instance of

scholarly article

0 references

title

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic (English)

0 references

main subject

visceral leishmaniasis

1 reference

1 reference

1 reference

1 reference

1

S Sundar

0 references

author name string

D K More

series ordinal

2

0 references

M K Singh

series ordinal

3

0 references

V P Singh

series ordinal

4

0 references

S Sharma

series ordinal

5

0 references

A Makharia

series ordinal

6

0 references

P C Kumar

series ordinal

7

0 references

H W Murray

series ordinal

8

0 references

language of work or name

English

0 references

publication date

October 2000

0 references

published in

Clinical Infectious Diseases

0 references

volume

31

0 references

page(s)

1104-7

0 references

issue

4

0 references

cites work

Clinicoepidemiological study of drug resistance in Indian kala-azar

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1086%2F318121

retrieved

21 January 2018

Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1086%2F318121

retrieved

21 January 2018

Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1086%2F318121

retrieved

21 January 2018

Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1086%2F318121

retrieved

21 January 2018

U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1086%2F318121

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F318121

retrieved

21 January 2018

Evidence that the High Incidence of Treatment Failures in Indian Kala‐Azar Is Due to the Emergence of Antimony‐Resistant Strains ofLeishmania donovani

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1086%2F318121

retrieved

21 January 2018

Clarification of comments on trial of aminosidine in visceral leishmaniasis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1086%2F318121

retrieved

21 January 2018

Use of the polymerase chain reaction to assess the success of visceral leishmaniasis treatment.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1086%2F318121

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F318121

retrieved

21 January 2018

(Q28142100)

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)